Drug intelligence / Profile preview

Raluridine

Development stage: Phase 1
Modality: Small Molecules

Overview

Raluridine is a small molecule drug classified as a pyrimidine nucleoside. It functions as an antimetabolite and pyrimidine antagonist, interfering with pyrimidine metabolism, which is essential for nucleic acid synthesis and cell proliferation. This investigational drug has been studied in clinical trials for the treatment of HIV Infections, reaching a maximum clinical trial phase of I.

Other names: 5-CHLORO-2',3'-DIDEOXY-3'-FLUOROURIDINEURIDINE, 5-CHLORO-2',3'-DIDEOXY-3'-FLUORO-

Targets

Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on Raluridine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Raluridine.

Explore the full profile